Press Releases April 30, 2026 04:05 PM

Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Elutia to announce Q1 2026 financial results and host a management webcast on May 14, 2026

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
ELUT

Elutia Inc., a Nasdaq-listed biotechnology company specializing in drug-eluting biomatrix technologies for medical devices, will report its first quarter 2026 financial results after market close on May 14, 2026. The company’s management will hold a webcast and conference call to discuss the results.

Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
ELUT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Elutia focuses on developing drug-eluting biomatrix products to improve compatibility between medical devices and patients.
  • The company aims to address needs in the growing implantable medical device market by humanizing medicine.
  • The Q1 2026 financial results will be revealed alongside a management commentary webcast for investors and analysts.

GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2026 financial results after market close on Thursday, May 14, 2026. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day.

The conference call can be accessed using the following information:

Webcast: Click here

Dial-In: Click here

To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call begins. If you forget your PIN prior to the conference call, you can simply re-register.

Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the “Investors” section of the Elutia website at http://investors.elutia.com/.

About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:
Elutia Investor Relations
[email protected]


Risks

  • Financial results could disappoint investors if revenues or margins fall short of expectations, impacting biotech sector sentiment.
  • As a company operating in medical technology, regulatory, clinical, and reimbursement challenges could affect future performance.
  • Market volatility or macroeconomic factors could influence investor reception to the quarterly earnings announcement.

More from Press Releases

WISeSat Announces $10 Million PIPE Investment Led by SEALSQ to Accelerate Space Cybersecurity and Post-Quantum Communications Oct 6, 2026 CN Reports Third Quarter Grain Movement Oct 6, 2026 Einride and EASE Logistics Are Now Live with Driverless Electric Trucks, Moving Freight Daily on Ohio Roads Oct 6, 2026 Nordic American Tankers Ltd (NYSE: NAT) - The Hansson family now collectively own 12 million NAT shares Oct 6, 2026 Evolution Metals & Technologies Selects INERGX to Power Planned 5 GW U.S. Facility, With Capacity Equivalent to Approximately 4 Mil-lion American Homes Oct 6, 2026